Compare Bristol-Myers Squibb Co (BMY) vs Hormel Foods Corp (HRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Hormel Foods Corp — how do they compare? Bristol-Myers Squibb Co trades at $58.81 (market cap $116.30B), while Hormel Foods Corp trades at $25.14 (market cap $13.65B). The key difference: Bristol-Myers Squibb Co is far larger — about 8.5× Hormel Foods Corp's market cap, and Hormel Foods Corp pays the higher dividend (4.72%). Which is the better fit depends on your goals.
| BMY | HRL | |
|---|---|---|
Market Cap | $116.30B | $13.65B |
Sector | Health | Consumer Staples |
52-Week High | $62.37 | $29.91 |
52-Week Low | $42.60 | $19.74 |
Enterprise Value | $152.24B | $15.65B |
Dividend Yield | 4.42% | 4.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Hormel Foods (HRL) trades at $24.46, down 1.11% on the day, with a neutral technical outlook and mixed analyst sentiment. The company has beaten earnings estimates for three consecutive quarters, though net income margin has compressed to 3.82% in 2025 from 6.75% in 2024. Recent strategic moves include the sale of its Brazilian Ceratti operations to focus on higher-growth markets, while maintaining its Dividend King status with 60 consecutive years of dividend increases.
The stock presents a value opportunity with a P/E of 28.78 and consensus price target of $26.33 (7.6% upside), but faces margin pressure from input cost inflation and competitive headwinds. The dividend yield of approximately 4.7% provides income support, though earnings stabilization remains key for sustained recovery from multi-year lows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →
